kabutan

HEALIOS K.K.(4593) Summary

4593
TSE Growth
HEALIOS K.K.
288
JPY
-27
(-8.57%)
Dec 12, 3:30 pm JST
1.84
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
289
Dec 12, 11:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
11.3
Yield
ー%
Margin Trading Ratio
18.69
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
318 JPY 2.04 USD
Previous Close Dec 11
315 JPY 2.01 USD
High Dec 12, 9:47 am
323 JPY 2.07 USD
Low Dec 12, 12:51 pm
255 JPY 1.63 USD
Volume
16,849,400
Trading Value
4.69B JPY 0.03B USD
VWAP
278.49 JPY 1.79 USD
Minimum Trading Value
28,800 JPY 184 USD
Market Cap
0.03T JPY 0.21B USD
Number of Trades
6,679
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
2,865
1-Year High Jul 17, 2025
31,879
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 1,601,300 13,491,600 8.43
Nov 28, 2025 1,534,800 14,171,200 9.23
Nov 21, 2025 1,564,900 13,836,800 8.84
Nov 14, 2025 1,587,700 13,639,200 8.59
Nov 7, 2025 1,612,700 15,691,100 9.73
Company Profile
HEALIOS K.K. develops treatments for intractable diseases using iPS cells. The company collaborates with Sumitomo Pharma and has a business alliance with Nikon.
Sector
Pharmaceuticals
HEALIOS K.K. conducts research and development of regenerative medicine products utilizing iPS cell technology. In the field of somatic stem cell regenerative medicine, the company is advancing the development of HLCM051 for acute cerebral infarction and ARDS (Acute Respiratory Distress Syndrome). In the iPSC regenerative medicine field, which involves transplanting cells with functions similar to the human body created by differentiating iPS cells, HEALIOS K.K. is developing a next-generation platform to create Universal Donor Cells (UDC) with reduced risk of immune rejection. The company's pipeline includes research and development in cancer immunotherapy, age-related macular degeneration treatment, and liver disease treatment. Through joint development with Sumitomo Pharma and collaborations with domestic and international research institutions, HEALIOS K.K. aims to realize new treatments for intractable diseases.